Cure & Immunotherapies
This Think Tank develops and tests targeted immunotherapies and therapeutic vaccines to decrease viral reservoirs and find cures for HIV and hepatitis B, and vaccines for syphilis, HPV, and hepatitis C.
-
CTNPT 047: Letermovir in ART-treated HIV-infected persons
Influence of a 3-month letermovir treatment on gut inflammation in ART-treated HIV-infected persons in an open labelled controlled randomized study
-
CTN 247: Canadian cohort of HIV+ slow progressors
A study of host and viral factors associated with disease progression in long term HIV infected subjects
-
CTN 246: Chloroquine to reduce T cell immune activation in HIV-infected individuals
Chloroquine as a modulator of T cell immune activation to improve CD4 recovery in HIV-infected participants receiving antiretroviral therapy: A proof-of-concept study
-
CTN 203: Phase I/II study of Remune® plus Amplivax™
A Phase I/II safety and immunogencity study of a combination of whole-killed HIV-1 antigen and Amplivax, administered with or without IFA, in HIV-1 infected Participants: Trial results
-
CTN 173: Vaccination before treatment interruption
A pilot study to determine the impact of therapeutic HIV vaccination followed by a scheduled interruption of antiretroviral therapy on HIV-specific immune function and virologic rebound in patients with prolonged viral suppression: Trial results
-
CTN 164: Treatment Interruption
A Prospective Randomized Trial of Structured Treatment Interruption (STI) Followed by the Initiation of a New Antiretroviral Regimen vs. Immediate Switching to a New Antiretroviral Regimen in HIV-Infected Patients Experiencing Virologic Failure on HAART
-
CTN 161: Simplified Protease Inhibitor Trial (SPRINT)
An International, Open-Label, Randomized, Multicentre Study to Evaluate the Antiviral Effect, Tolerability, Safety and Pharmacokinetics of Fortovase (saquinavir SGC) and Norvir (ritonavir) QD vs. Crixivan (indinavir) and Norvir (ritonavir) BID in HIV-Infected Patients
-
CTN 160: The Double Non-Nucleoside Study (2NN Study)
An Open-Label, Comparative Study to Evaluate the Antiviral Efficacy and Safety of Nevirapine and Efavirenz or Both Drugs Combined in Combination with d4T and 3TC. (The 2NN or Double Non-Nucleoside Study): Trial results